AACR 2024 Annual meeting

Efficacy of the STC-1010 a new allogenic cancer vaccine in different colorectal cancer models  F. Ghiringhelli et al, Cancer Res 2024 https://doi.org/10.1158/1538-7445.AM2024-5003 Link to Poster

SITC 2023 Annual meeting

Stimulated tumor cells (STC) vaccine induce response in colorectal cancer A. Italiano et al, J for ImmunoTherapy of Cancer, 2023 http://dx.doi.org/10.1136/jitc-2023-SITC2023.1132 Link to Poster   DOWNLOAD PRESS RELEASE

ASCO annual meeting 2023

Efficacy of STC-1010, a new allogenic cancer vaccine in colorectal cancer models F.Ghiringhelli et al, J Clin Oncol, 2023 (suppl 16; abstr e14661) 10.1200/JCO.2023.41.16_suppl.e14661 Link to Abstract

AACR Annual meeting 2023

Inovative in vivo (in ovo) CAM model to predict efficacy and mode of action of a new antitumor vaccine stc-1010 on human colorectal adenocarcinoma F. Ghiringhelliet al, Cancer Res 2023; 6791. https://doi.org/10.1158/1538-7445.AM2023-6791 Link to poster   STC-1010 a new therapeutic vaccine promotes tumor cell death A. Italiano et al, Cancer Res 2023; LB224.https://doi.org/10.1158/1538-7445.AM2023-LB224 Link to Poster

SITC annual meeting 2022

Efficacy study of STC-1010 antitumor vaccine associated with standard chemotherapies on MC 38 syngeneic colon cancer tumor model F. Ghiringhelli et al, Journal for ImmunoTherapy of Cancer 2022; 1179 doi: 10.1136/jitc-2022-SITC2022.1179 Link to poster   Inovative in vivo (in ovo) cam model to predict efficacy and mode of action of a new antitumor vaccine stc-1010 on […]

AACR annual meeting 2022

Sensitizing potential of a novel stimulated and haptenized vaccine in immunotherapy resistant metastatic colorectal cancer R. Boidot et al, Cancer Res 2022; 3566. https://doi.org/10.1158/1538-7445.AM2022-3566 Link to Poster   Antitumor activity of a novel allogeneic colorectal cancer vaccine in C57BL/6 mice bearing MC38 anti-PD1 resistant colon carcinoma syngeneic model with TME A. Italiano et al, Cancer […]

AACR 2021 Annual Conference

Efficacy results of a novel vaccine composed of stimulated and haptenized tumors cells in Balbc mice grafted with murine colon adenocarcinoma CT26 cells C. Gongora et al, Cancer Immunol Res 2022; P003. https://doi.org/10.1158/2326-6074.TUMIMM21-P003 Link to PDF presentation


Brenus’ manufacturing process overpasses the lack of immunogenicity & educates the immune system  with visible and multi-specific targets


Selection criteria of starting material (Allogeneic tumor cell lines)

  • Representative oncogenic drivers (TP53,BRAF,KRAS,…)
  • Cold & hot tumor cell lines
  • Resistances capacities (metabolic ; chemical & physical)

Increase antigenicity

Brenus’ manufacturing process overpasses the lack of antigenicity & educates the immune system  with broad & higher quality range of tumor antigens